BTIG’s Dane Leone has upgraded Juno Therapeutics Inc
“We continue to think that Sell-side estimates for the CD19 CAR T class are too high, but acknowledge that Buy-side expectations are more inline with our model,” Leone wrote in a note.
The analyst said the JCAR017 dataset in DLBCL is small, and 10 of 11 patients within the response group had undergone prior transplant. But, the analyst said they still lack data on response rates in the worst r/r DLBCL group, which is also the largest patient population.
Although toxicity seems slightly favorable to
Late August, Leone initiated coverage of the company with a
|Nov 2016||BTIG Research||Upgrades||Sell||Neutral|
|Aug 2016||BTIG Research||Initiates Coverage on||Sell|
|Jul 2016||Barclays||Initiates Coverage on||Equal-Weight|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.